Evidence map›Paper›PMID 30328058›Full record

Trial reportEuropean journal of drug metabolism and pharmacokinetics2019

Improved Oral Absorption of Quercetin from Quercetin Phytosome®, a New Delivery System Based on Food Grade Lecithin.

Antonella Riva, Massimo Ronchi, Giovanna Petrangolini, Stefania Bosisio, Pietro Allegrini

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in European journal of drug metabolism and pharmacokinetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07760506 (The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health - A Randomized, Double-Blind, Placebo-Controlled Study), which is not on this map. Cited by 126 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07760506 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health - A Randomized, Double-Blind, Placebo-Controlled Study

TypeinterventionalSponsorApplied Science & Performance InstituteRan2026 to 2028Enrolled60ConditionsHealthy Aging, Inflammaging, Metabolic Health, QuercetinArmsQuercetin (dietary supplement), Coenzyme Q10, Rice Flour
3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 1 synthesis or guideline pooled it, 252 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. The effect of quercetin and citrulline on cycling time trial performance.Journal of the International Society of Sports Nutrition · 2024
    Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Frontiers in molecular biosciences · 2026
    Article
  20. Article

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Antonella RivaResearch and Development Department, Indena SpA, 20139, Milan, Italy. antonella.riva@indena.com.ORCID http://orcid.org/0000-0003-2819-943X
Massimo RonchiResearch and Development Department, Indena SpA, 20139, Milan, Italy.
Giovanna PetrangoliniResearch and Development Department, Indena SpA, 20139, Milan, Italy.
Stefania BosisioResearch and Development Department, Indena SpA, 20139, Milan, Italy.
Pietro AllegriniResearch and Development Department, Indena SpA, 20139, Milan, Italy.
Indena (Italy) · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThe importance of quercetin and flavonoids in the diet and as food supplements is well known, and literature studies support their potential use to treat several human diseases. Many beneficial properties have been described for quercetin, so much effort has been directed into overcoming the major drawbacks of this natural compound-its poor solubility and low oral absorption. The aims of this study were to compare a new food-grade lecithin-based formulation of quercetin, Quercetin Phytosome

methodsThe solubility of the new formulation was determined by in vitro incubation in simulated gastrointestinal fluids, and quercetin was detected by ultra performance liquid chromatography. A single-dose, randomized, six-sequence/three-period crossover clinical trial (3 × 3 × 3 crossover design) with a balanced carryover effect was conducted in healthy volunteers under fasting conditions. Twelve healthy volunteers of both sexes with an age range of 18-50 years were recruited; one dose of quercetin and two different doses of Quercetin Phytosome were administered orally as film-coated tablets. Pharmacokinetic samples were collected at twelve time points (from 0 h to 24 h) after administration, and quercetin levels were measured by HPLC/MS/MS. Data were analyzed using the Phoenix WinNonlin (v.6.4) software package, and the most significant pharmacokinetic parameters were calculated. Statistical analysis involved performing a two-way ANOVA with repeated measures followed by post hoc analysis (Tukey's test).

resultsSignificant improvements in both in vitro solubility and oral absorption (in terms of both exposure and maximum concentration achieved) by healthy volunteers in a human clinical study were obtained with the Quercetin Phytosome formulation as compared to unformulated quercetin.

conclusionsA more soluble formulation of quercetin based on lecithin, Quercetin Phytosome, has recently been developed, and was found to facilitate the attainment of very high plasma levels of quercetin-up to 20 times more than usually obtained following a dose of quercetin-when the novel formulation was administered orally in human volunteers, and it did not have any notable side effects. These results suggest that Quercetin Phytosome allows the oral administration of quercetin in a safe and bioavailable manner, thus facilitating the effective utilization of this natural compound to treat various human diseases.

Indexed as

Administration, OralAdolescentAdultCross-Over StudiesDose-Response Relationship, DrugDrug Delivery SystemsFastingFemaleHumansLecithinsLiposomesMaleMiddle AgedOral Mucosal AbsorptionQuercetinYoung AdultLecithinsLiposomesQuercetin

Identifiers

PMID30328058
PMCPMC6418071
OpenAlexW2895939394

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.